From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

By Sharon AtienoThough more than 200 million people worldwide are affected by schistosomiasis (bilharzia), Africa bears the biggest brunt reporting nine out of ten cases globally. As such, a ...

The Rare Blood Donor Registry was launched at the National Conclave of Blood Transfusion Services in Kochi, attended by ...

Introduction Therapeutic antibodies are laboratory-engineered proteins designed to replicate the immune system's natural ability to combat dise ...

The Patent Eligibility Restoration Act (PERA) proposes a solution to a complex debate: What can be patented, and when do ...

TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia. See ...

The growth of the vaccine technologies market is driven by rise in prevalence of infectious diseases, growing trend towards preventive healthcare, and government immunization programs and initiatives.

A neoantigen-targeting personalized cancer vaccine may be effective as adjuvant therapy in patients with high-risk clear cell renal cell carcinoma, phase 1 data suggest.